Experimental selective elevation of renal medullary blood flow in hypertensive rats: evidence against short-term

B Bądzyńska1, J Sadowski

  • 1Laboratory of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre of the Polish Academy of Sciences, Warsaw, Poland.

Abstract

Insights

Selective increases in renal medullary blood flow using bradykinin did not significantly lower blood pressure in hypertensive rats. This suggests enhanced medullary perfusion is not a short-term antihypertensive mechanism in these models.

Area of Science:

  • Cardiovascular Physiology
  • Renal Physiology
  • Hypertension Research

Background:

  • Renal medullary blood flow (MBF) can be increased by bradykinin (Bk) in normotensive rats.
  • The effect of selectively increased MBF on blood pressure (BP) in hypertension is not well understood.

Purpose of the Study:

  • To investigate if selective increases in renal medullary perfusion can cause a short-term decrease in blood pressure (BP) in rat models of arterial hypertension.
  • To determine if this BP decrease is independent of renal excretion and fluid depletion.

Main Methods:

  • Rats were rendered hypertensive using noradrenaline, angiotensin II, high-salt diet, or a combination.
  • Bradykinin was infused intrarenally or intravenously to selectively increase medullary perfusion.
  • Blood pressure and renal blood flow were monitored.

Main Results:

  • Bradykinin increased outer- and inner-medullary blood flow by 10-50% depending on the hypertension model.
  • Total renal blood flow increased by less than 3%.
  • A minor decrease in BP (<3%) was observed only in rats acutely induced hypertensive by noradrenaline or angiotensin II, and was not correlated with medullary perfusion increases.

Conclusions:

  • Substantial selective increases in renal medullary perfusion did not cause a short-term decrease in blood pressure in hypertensive rats.
  • Enhanced medullary perfusion is unlikely to be a short-term mechanism for lowering blood pressure in these models of hypertension.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...